Houston, TX, (January 12, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announced that Dr. Yin Chen, Vice President of Research and Development has been invited to present the results of experiments leading to identification of novel antibacterial agents at the Keystone Symposia Meeting the Challenges of Drug Discovery conference to be held January 15th through the 20th 2005, in Vancouver, British Columbia.
Dr. Chen's presentation describes the discovery of new antibacterial targets and agents that defeat bacteria antibiotic resistance mechanisms. It is titled "A novel genomic approach identifies bacterial DNA-dependent RNA polymerase as a target of an antibacterial oligodeoxynucleotide, RBL1".
Since 1972, Keystone Symposia www.keystonesymposia.org a non-profit institution, serves as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas, and acceleration of applications that benefit society.
Dr. Malcolm Skolnick, CytoGenix President and CEO commented, "One of our company's most important goals is demonstrating the quality of our work to our scientific peers. We are pleased that Dr. Chen is presenting the results of our latest research at this prestigious venue to portray the scientific merit and potential medical benefit of these results."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Communications Director — Juan Ferreira, (407) 774-9949
